Fortress Biotech to Participate in the 20th Annual Needham Virtual Healthcare Conference
April 07, 2021 08:30 ET
|
Fortress Biotech, Inc.
NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or...
Fortress Biotech Reports Record 2020 Financial Results and Recent Corporate Highlights
March 31, 2021 16:15 ET
|
Fortress Biotech, Inc.
Revenue from marketed dermatology products increased 28% for full-year 2020 compared to 2019 Our partner company, Cyprium Therapeutics, and Sentynl Therapeutics, a wholly-owned subsidiary of the...
Fortress Biotech’s Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane® for the Treatment of Severe Recalcitrant Nodular Acne
March 22, 2021 09:00 ET
|
Fortress Biotech, Inc.
NEW YORK and SCOTTSDALE, Ariz., March 22, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that Journey Medical Corporation (“Journey Medical”), a partner...
Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences
March 04, 2021 08:00 ET
|
Fortress Biotech, Inc.
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...
Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
February 26, 2021 08:00 ET
|
Fortress Biotech, Inc.
NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...
Cyprium Therapeutics, a Fortress Biotech Partner Company, and Sentynl Therapeutics, a Wholly-owned Subsidiary of the Zydus Group, Sign Development and Asset Purchase Agreement for Cyprium Therapeutics’ Copper Histidinate Product Candidate for Treatment of Menkes Disease
February 24, 2021 08:00 ET
|
Fortress Biotech, Inc.
Sentynl acquires CUTX-101, Copper Histidinate, for $20 million in upfront and regulatory milestone payments through NDA approval, as well as potential sales milestones plus royalties Cyprium will...
Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences
January 05, 2021 08:30 ET
|
Fortress Biotech, Inc.
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...
Fortress Biotech Announces Breakthrough Therapy Designation for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease
December 15, 2020 08:00 ET
|
Fortress Biotech, Inc.
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...
Fortress Biotech Ranked in Deloitte’s Technology Fast 500™ for the Second Year in a Row
November 18, 2020 08:00 ET
|
Fortress Biotech, Inc.
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...
Fortress Biotech Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights
November 09, 2020 16:20 ET
|
Fortress Biotech, Inc.
Product revenue for the first nine months of 2020 increased 29% year-over-year to $30.8 million Rolling submission of the New Drug Application for CUTX-101 is expected to begin in the first quarter...